Company intelligence / Profile preview

AIO-Studien-gGmbH

Berlin, Berlin, Germany

Ownership: Private
Development stage: Other

Overview

AIO-Studien-gGmbH has established non-interventional and interventional multi-center clinical research platforms in oncology, notably CRISP for lung cancer and GOBLET (phase 1/2) for advanced/metastatic gastrointestinal tumors; the GOBLET trial showed promising immune activation and disease control rates in first-line metastatic PDAC patients (62% overall response rate, 85% disease control rate, 45% 12-month survival rate)

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyOncolytic virus therapySmall molecule
Industry: Academic Hospital/University/Research

Partnerships

Innoplexus (AIO data hub initiative, AI-driven life sciences data collaboration)Oncolytics Biotech (management of GOBLET trial)iOMEDICO AG (project management and analyses for CRISP)

Beyond the preview

Go deeper on AIO-Studien-gGmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIO-Studien-gGmbH.

Explore the full profile